[go: up one dir, main page]

WO2004098630A1 - Inhibiteur de troubles menopausiques - Google Patents

Inhibiteur de troubles menopausiques Download PDF

Info

Publication number
WO2004098630A1
WO2004098630A1 PCT/JP2004/006391 JP2004006391W WO2004098630A1 WO 2004098630 A1 WO2004098630 A1 WO 2004098630A1 JP 2004006391 W JP2004006391 W JP 2004006391W WO 2004098630 A1 WO2004098630 A1 WO 2004098630A1
Authority
WO
WIPO (PCT)
Prior art keywords
index
menopause
inhibitor
disorder inhibitor
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2004/006391
Other languages
English (en)
Japanese (ja)
Inventor
Masaji Matsunaga
Shunji Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Nissei Bio Co Ltd
Original Assignee
Nissan Chemical Corp
Nissei Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp, Nissei Bio Co Ltd filed Critical Nissan Chemical Corp
Priority to JP2005506023A priority Critical patent/JP3975448B2/ja
Publication of WO2004098630A1 publication Critical patent/WO2004098630A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Definitions

  • the present invention relates to a climacteric disorder inhibitor that can effectively suppress various unpleasant symptoms during menopause, that is, a so-called climacteric disorder, and a health food containing the effective amount thereof. .
  • Sudden heat such as hot flashes or hot flashes.
  • Osteoporosis hyperlipidemia, arteriosclerosis, etc.
  • Hormone replacement therapy is not available for menopausal women. This is a method of treating or suppressing menopausal disorders by replenishing strogen or progestogen) with a preparation in the form of an oral solution or patch.
  • strogen or progestogen a preparation in the form of an oral solution or patch.
  • Chinese medicine therapy is sometimes used.
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2001-069946
  • Patent Document 2 JP-A-2003-113117
  • hormone replacement therapy is effective in treating or suppressing menopause, there is a risk that various side effects (eg, an increased incidence of breast cancer, uterine cancer, etc.) may occur.
  • side effects eg, an increased incidence of breast cancer, uterine cancer, etc.
  • Kampo therapy must be performed strictly based on the instructions of a specialist, and are not simple methods.
  • an object of the present invention is to provide a menopausal disorder inhibitor that can effectively suppress menopausal disorders and a health food containing the effective amount thereof.
  • the present inventors have conducted intensive studies on the control of menopause, and as a result, have found that nucleoprotamine can effectively suppress menopause, and completed the present invention.
  • the climacteric disorder inhibitor of the present invention is characterized by containing nucleoprotamine as an active ingredient.
  • nucleoprotamine obtained from milt of fish can be used.
  • Said fish may be salmon, trout, herring or ⁇ .
  • the health food of the present invention is characterized by containing an effective amount of the present climacteric disorder inhibitor.
  • the climacteric disorder inhibitor of the present invention can be easily orally ingested and, by taking an appropriate amount without side effects, can effectively suppress a wide range of climacteric disorders.
  • the health food of the present invention contains an effective amount of the present menopausal inhibitor, and can be appropriately selected from various forms such as solid, liquid, jelly, and paste. It is suitable for daily intake.
  • Nucleoprotamine which is an active ingredient of the climacteric disorder inhibitor of the present invention, is a complex in which protamine, which is a basic protein present in mature sperm nuclei of vertebrates, binds to nucleic acids to form a complex. , Form sperm chromatin.
  • Protamine has a low molecular weight (usually less than 10,000), and most of the constituent amino acids are basic amino acids, especially arginine. Nitrogen derived from arginine is equivalent to 2590% of the total nitrogen content, and acidic amino acids are Usually not included.
  • Arginine has a wide variety of physiological effects, and has a sedative effect, an endocrine stimulating effect, a maintenance effect on gastrointestinal functions, and the like.
  • Nucleoprotamine is abundant in fish, for example, milts such as salmon, trout, herring, and ⁇ . For example, after removing skins, muscles, blood vessels, and the like from milt of fish, drying and extraction are performed. It can be produced by purification by a conventional method, and may be in various forms such as powder, granule, paste, and liquid.
  • nucleoprotamine By taking nucleoprotamine, it is possible to take protamine and nucleic acid at the same time.
  • nucleic acids There are two types of nucleic acids: deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Saved. Fish milt contains abundant DNA containing four nucleotides, adenine (A), thymine (T), guanine (G) and cytosine (C). Nucleic acids have the effect of activating cells and preventing senescence.
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • the form of use of the climacteric disorder inhibitor of the present invention is not particularly limited, and examples thereof include powders, granules, tablets, capsules, jellies, pastes, and various forms of health foods (including health drinks). May be.
  • the health drink may be, for example, an aqueous solution, a suspension, or the like.
  • Nucleoprotamine can be used as it is as the climacteric disorder inhibitor of the present invention, and if desired, other active ingredients (eg, vitamins and the like) may be added in an appropriate amount.
  • the content of nucleoprotamine in the climacteric disorder inhibitor of the present invention or the content of the climacteric disorder inhibitor in the health food of the present invention is appropriately selected as desired.
  • the health food of the present invention may contain, besides the present menopause inhibitor, those that can be added to ordinary foods.
  • the climacteric disorder inhibitor of the present invention preferably ingests an amount of, for example, 0.1 to 10 g, preferably 0.2 to 5 g per day, for example.
  • the climacteric disorder inhibitor of the present invention may be ingested once to three times a day, but the dosage may be appropriately increased or decreased depending on age, body weight, symptoms of climacteric disorder and the like.
  • the climacteric disorder inhibitor of the present invention was produced from salmon milt by the following procedure.
  • Salmon milt lOOOOg was taken, and blood was removed and washed with water. After draining, 300 mL of water was added, and the mixture was ground and stirred to obtain a suspension.
  • the suspension was filtered to remove solids such as milt, and then spray-dried with a spray drier to obtain a powdery substance.
  • the powdery substance is washed with ethanol to remove ethanol-soluble matter and moisture, and dried under reduced pressure. After drying, 180 g of the present climacteric disorder inhibitor was obtained as a powder.
  • menopause inhibitor is a pale yellow powder containing nucleoprotamine as a main component, and its chemical and physical properties are as follows.
  • Protein content 25-60% by mass
  • Ash content 5-15% by mass
  • Tatsu Perman index was calculated based on Table 1 below.
  • each symptom belonging to the syndromes in Table 1 can be further subdivided into several types of symptoms. Taking the example of perceptual impairment-like symptoms as examples, the perceptual impairment-like symptoms can be divided into two types, a symptom of numbness in the limbs and a symptom of dull limbs. Then, for each of the symptom "numbness in the limbs" and the symptom "dullness in the limbs", the intensity of the symptom is represented by a number from 0 to 3.
  • the Kupperman index of each symptom belonging to the syndromes in Table 1 is calculated by the following formula (I).
  • Kupperman index (total) The sum of the Kupperman indexes (Kupperman index (total)) for each of the 11 symptoms shown in Table 1 is the Kupperman index for menopause.
  • the degree of menopause is determined from the Kuppa-Man index (total) based on the following criteria.
  • the menopause index was used as an index of the therapeutic effect of menopause.
  • the menopause index is calculated by the following equation (II).
  • the therapeutic effect of menopause is determined from the menopause index based on the following criteria.
  • the menopause index is 0.66, which is in the range of 0.3 to 0.7.
  • Treatment of climacteric disorders with a climacteric disorder inhibitor was determined to be effective.
  • Vasomotor disorders 86/128 ⁇ 0.67
  • the climacteric disorder inhibitor of the present invention is useful for inhibiting a wide range of symptoms.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à un inhibiteur de troubles ménopausiques comprenant une nucléoprotamine en tant que principe actif, ainsi qu'à un aliment destiné à favoriser une bonne santé, qui renferme une dose efficace de cet inhibiteur de troubles ménopausiques. Ladite nucléoprotamine est un complexe qui résulte de l'association entre un acide nucléique et une protamine, une protéine simple qui est contenue dans les noyaux de spermatozoïdes matures de vertébrés, et qui peut provenir, par exemple de variétés albinos de poissons tels que le saumon, la truite, le hareng ou le lieu jaune. Divers désagréments et symptômes subjectifs associés aux troubles ménopausiques peuvent être inhibés efficacement, par administration adéquate dudit inhibiteur de troubles ménopausiques ou aliment, à des intervalles fixes, par exemple quotidiennement.
PCT/JP2004/006391 2003-05-12 2004-05-12 Inhibiteur de troubles menopausiques Ceased WO2004098630A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005506023A JP3975448B2 (ja) 2003-05-12 2004-05-12 更年期障害抑制剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003133200 2003-05-12
JP2003-133200 2003-05-12

Publications (1)

Publication Number Publication Date
WO2004098630A1 true WO2004098630A1 (fr) 2004-11-18

Family

ID=33432187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/006391 Ceased WO2004098630A1 (fr) 2003-05-12 2004-05-12 Inhibiteur de troubles menopausiques

Country Status (2)

Country Link
JP (1) JP3975448B2 (fr)
WO (1) WO2004098630A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63192720A (ja) * 1987-02-05 1988-08-10 Riken Vitamin Co Ltd 抗菌製剤
US5187260A (en) * 1988-09-06 1993-02-16 Sharifa Karali Process for the preparation of a high purity protamine-DNA complex and process for use of same
WO1994018947A1 (fr) * 1993-02-16 1994-09-01 Sharifa Karali Complexe protamine-adn de haute purete et son utilisation
JPH09191852A (ja) * 1996-01-19 1997-07-29 Sennosuke Tokumaru 健康食品
JPH10165138A (ja) * 1996-12-04 1998-06-23 Biken Corp:Kk 美容健康食品

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63192720A (ja) * 1987-02-05 1988-08-10 Riken Vitamin Co Ltd 抗菌製剤
US5187260A (en) * 1988-09-06 1993-02-16 Sharifa Karali Process for the preparation of a high purity protamine-DNA complex and process for use of same
WO1994018947A1 (fr) * 1993-02-16 1994-09-01 Sharifa Karali Complexe protamine-adn de haute purete et son utilisation
JPH09191852A (ja) * 1996-01-19 1997-07-29 Sennosuke Tokumaru 健康食品
JPH10165138A (ja) * 1996-12-04 1998-06-23 Biken Corp:Kk 美容健康食品

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DURHAM B.H. ET AL.: "Protamine precipitable cytosolic receptors for oestradiol and progesterone in pre-menopausal human endometrial tissue", MED. SCI. RES., vol. 17, 1989, pages 1039 - 1041, XP002980985 *

Also Published As

Publication number Publication date
JPWO2004098630A1 (ja) 2006-07-13
JP3975448B2 (ja) 2007-09-12

Similar Documents

Publication Publication Date Title
WO2016188091A1 (fr) Utilisation de nicotinamide mononucléotide pour la préparation d'un médicament indiqué pour prévenir ou lutter contre l'athérosclérose et les maladies cardiovasculaires et cérébrovasculaires, et médicament associé
CN103463539A (zh) 一种治疗湿疹的药物及其制备方法和用途
KR101689259B1 (ko) 데커신 및/또는 데커시놀 안젤레이트 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물, 쌀눈 추출물, 무말랭이 추출물을 유효성분으로 포함하는 운동에 기한 피로 또는 스트레스의 예방 또는 회복용 조성물
CN104740451A (zh) 一种治疗高尿酸血症的中药组合物及其应用
CN103623002A (zh) 一种保健关节组合物
CN103610795B (zh) 一种杜仲降压口服制剂的制备方法
CN104349786B (zh) 骨骼肌慢肌化剂
WO2016188092A1 (fr) Utilisation de nicotinamide mononucléotide pour la préparation d'un produit naturel indiqué pour prévenir ou lutter contre l'athérosclérose et les maladies cardiovasculaires et cérébrovasculaires, et produit naturel associé
WO2004098630A1 (fr) Inhibiteur de troubles menopausiques
CN1315411C (zh) 一种具有通便美容功能的保健品及制备方法
JP7271016B2 (ja) 骨損失疾患の予防、改善または治療のためのｃｈｐ（シクロ－ヒスプロ）および副甲状腺ホルモンを含む組成物の用途
CN102824414A (zh) 一种用于治疗便秘的药茶
CN103719661B (zh) 补血口服液保健品
CN107050060A (zh) 治疗牛皮癣的外用药及药物组合物
CN107260967A (zh) 一种治疗痛风的药物组合物
TWI309983B (en) Medicine for inhibiting climacteric symptom
CN1242766C (zh) 一种预防和治疗慢性疲劳综合症的药物及其制备方法
CN102319330A (zh) 一种治疗骨质增生的中药巴布膏及其制备方法
RU2076731C1 (ru) Средство и способ повышения неспецифической резистентности организма при заболеваниях внутренних органов
JP4521488B2 (ja) 線維筋痛症候群の治療剤並びに筋攣縮による疼痛の治療剤
CN100391524C (zh) 一种防治骨质疏松症的药物制剂及其制备方法
CN101143203A (zh) 一种具有护肝养胃功能的复方口服液
CN110693877B (zh) 穿心莲内酯在制备用于预防或/和治疗肌少症的药物中的应用
JP2007077051A (ja) 新規な化合物、肥満改善剤、脂質代謝改善剤、血糖降下剤及び育毛改善剤
WO2005079824A1 (fr) Boisson ou médicament contenant des extraits de bambou comme ingrédient principal

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005506023

Country of ref document: JP

122 Ep: pct application non-entry in european phase